Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation

Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following transplantation Investigator-sponsored Phase 1 trial underway at the Ajmera Transplant Centre, University Health Network (UHN), Toronto, a world-renowned transplant center, conducted by Professor Atul HumarBuilds on preclinical human kidney proof-of-concept data published in the American Journal of Transplantation demonstrating that SYN002 is associated with >90% reduction in CMV reactivation from latency COPENHAGEN, Denmark, May 28, 2026 (GLOBE NEWSWIRE) -- Synklino A/S, a clinical-stage biotechnology company developing a first-in-class, ex vivo therapy to transform kidney transplantation outcomes through better CMV prevention, today announces the first patient has been dosed in a first-in-human Phase 1 clinical trial of SYN002 for the prevention of cytomegalovirus (CMV) reactivation in kidney transplant recipients.